117 related articles for article (PubMed ID: 6367856)
1. Adjuvant chemotherapy in stage-II breast cancer: an overview of the NSABP clinical trials.
Wolmark N; Fisher B
Breast Cancer Res Treat; 1983; 3 Suppl():S19-26. PubMed ID: 6367856
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
3. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer.
Fisher B; Fisher ER; Redmond C
J Clin Oncol; 1986 Jun; 4(6):929-41. PubMed ID: 3519883
[TBL] [Abstract][Full Text] [Related]
4. Disease-free survival at intervals during and following completion of adjuvant chemotherapy: the NSABP experience from three breast cancer protocols.
Fisher B; Redmond C; Wolmark N; Wieand HS
Cancer; 1981 Sep; 48(6):1273-80. PubMed ID: 7023651
[TBL] [Abstract][Full Text] [Related]
5. 1-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers.
Fisher B; Sherman B; Rockette H; Redmond C; Margolese R; Fisher ER
Cancer; 1979 Sep; 44(3):847-57. PubMed ID: 383274
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
[TBL] [Abstract][Full Text] [Related]
7. Pathologic findings from the National Surgical Adjuvant Breast Project. VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation.
Fisher ER; Redmond C; Fisher B
Cancer; 1983 Jan; 51(2):181-91. PubMed ID: 6821810
[TBL] [Abstract][Full Text] [Related]
8. Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience.
Fisher B; Redmond C; Fisher ER; Wolmark N
NCI Monogr; 1986; (1):35-43. PubMed ID: 3534589
[TBL] [Abstract][Full Text] [Related]
9. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base.
Jones SE; Moon TE; Bonadonna G; Valagussa P; Rivkin S; Buzdar A; Montague E; Powles T
Am J Clin Oncol; 1987 Oct; 10(5):387-95. PubMed ID: 3310603
[TBL] [Abstract][Full Text] [Related]
10. NSABP trials of adjuvant chemotherapy for breast cancer. A further look at the evidence.
Mueller CB; Lesperance ML
Ann Surg; 1991 Sep; 214(3):206-11; discussion 211-2. PubMed ID: 1670113
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy of breast cancer: Southwest Oncology Group studies.
Osborne CK; Rivkin SE; McDivitt RW; Green S; Stephens RL; Costanzi JJ; O'Bryan R
NCI Monogr; 1986; (1):71-4. PubMed ID: 3534592
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.
Fisher B; Redmond C; Brown A; Fisher ER; Wolmark N; Bowman D; Plotkin D; Wolter J; Bornstein R; Legault-Poisson S
J Clin Oncol; 1986 Apr; 4(4):459-71. PubMed ID: 2856857
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary breast cancer with L-PAM/5-FU and tamoxifen: an interim report.
Fisher B
Breast Cancer Res Treat; 1983; 3 Suppl():S7-17. PubMed ID: 6367863
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy of breast cancer: the Southwest Oncology Group experience.
Knight WA; Rivkin SE; Glucksberg H; Foulkes MA; Costanzi JJ; Stephens RL; Athens JW; O'Bryan RM
Breast Cancer Res Treat; 1983; 3 Suppl():S27-33. PubMed ID: 6367857
[TBL] [Abstract][Full Text] [Related]
15. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
Fisher B; Redmond C; Legault-Poisson S; Dimitrov NV; Brown AM; Wickerham DL; Wolmark N; Margolese RG; Bowman D; Glass AG
J Clin Oncol; 1990 Jun; 8(6):1005-18. PubMed ID: 2189950
[TBL] [Abstract][Full Text] [Related]
16. Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents.
Glass A; Wieand HS; Fisher B; Redmond C; Lerner H; Wolter J; Shibata H; Plotkin D; Foster R; Margolese R; Wolmark N
Cancer Treat Rep; 1981; 65(5-6):363-76. PubMed ID: 7016322
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy for breast cancer: a brief overview of the NSABP experience and some thoughts on neoadjuvant chemotherapy.
Fisher B
Recent Results Cancer Res; 1986; 103():54-68. PubMed ID: 3526476
[No Abstract] [Full Text] [Related]
18. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
19. Multiple trials of adjuvant chemohormonal therapy in the treatment of breast cancer: preliminary results--the ECOG experience.
Carbone PP
Breast Cancer Res Treat; 1983; 3 Suppl():S35-8. PubMed ID: 6367858
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.
Glucksberg H; Rivkin SE; Rasmussen S; Tranum B; Gad-el-Mawla N; Costanzi J; Hoogstraten B; Athens J; Maloney T; McCracken J; Vaughn C
Cancer; 1982 Aug; 50(3):423-34. PubMed ID: 7046900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]